The power of giving
In medicine, support from funds is crucial for researchers wanting to move their work forward. Neurologist Marianne de Visser and junior researcher Nienke Heida know this better than anyone. Heida is carrying out her PhD research at Amsterdam UMC, thanks in part to a grant from the Marianne de Visser Fund. Together, they discuss the importance of supporting early-career researchers.

Myositis is a neuromuscular disorder. 'There are hundreds of such disorders, but for most of them there is unfortunately still no effective treatment,'De Visser explains. In myositis, muscles become inflamed, which damages the muscle cells. As a result, patients experience pain and a loss of muscle strength. 'The disease can be detected in childhood,' says De Visser. 'In that case, it is often hereditary, but much more often it develops later in life.' Sadly, only around 35 per cent of people with myositis currently make a full recovery after treatment. That is why research into the disease has been conducted at Amsterdam UMC for more than 25 years, with the aim of continually improving diagnosis and treatment, and thereby the quality of life of patients.
Understanding the disease
Heida’s PhD research contributes to this effort. 'My work focuses on rehabilitation and registration,'she explains. 'We do not actually understand many conditions, such as myositis, very well yet. And myositis also has a very diverse disease course.' Good patient registration helps to deepen understanding of the disease. Heida is working on setting up these patient registries, in which data on patients coming from clinical care are stored in a structured way.
'In addition, we ask patients to complete questionnaires on topics such as fatigue and physical functioning,' she says. This makes it possible to conduct long-term research into the disease, and also makes it easier to invite patients to take part in studies that may benefit them. Ultimately, Heida hopes to roll out the myositis registry to other hospitals too, so that a national picture of the disease can emerge.
Data can change lives
This makes a major difference for patients as well, because far more research is still needed into the early stages of the disease. Heida: 'We are working on ensuring that the registry receives an automatic signal as soon as there is a new myositis patient. That is important, because we want to conduct more research into the early phase of the disease. That way, patients can receive the best possible therapy right from the start.'
De Visser has also seen this importance reflected in her own research practice. 'For a long time, doctors treating patients with myositis assumed that their patients were mainly suffering from symptoms such as muscle weakness, difficulty swallowing and lung problems. But patients reported something quite different: they were most affected by fatigue, pain and reduced physical activity. Since then, we have also started to include these symptoms in our research.' In this way, insights from patients can change the direction of research.
A first opportunity for young researchers
For many young researchers, an academic career does not begin with certainty, but with a puzzle. This was also true for Heida: when she started at Amsterdam UMC, there was funding for one and a half years of research. Enough to get started, but not enough for a full PhD trajectory. Thanks to the Marianne de Visser Fund, she was nevertheless able to begin setting up a myositis registry.
'You cannot establish registries in just a few months,' Heida explains. 'You need time to build collaborations and to set up systems properly.' It was precisely this initial support that proved decisive. The work on the registry grew into several research projects and eventually into a PhD position, funded in part by the Prinses Beatrix Spierfonds and ZonMw.
Giving is more necessary than ever
Finding funding for scientific research remains difficult, De Visser notes: every year, many more research proposals are submitted to funding bodies than can actually be supported. This is precisely why De Visser considers private support so important. After her retirement, she decided not only to make donations to the UvA Fund, but also to include her fund in her will.
'I actually hope that there will be no money left in the fund at the end of the year,' she says with a smile. 'Then I know that everything has been well spent on research that improves lives.' For Heida, it ultimately all comes down to the patients. She speaks every day with people who are hoping for better treatments and greater understanding of their condition. 'We are capable of so much nowadays,' she says. 'But we have to make sure that research remains possible.'